A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Brief description of study

This is a study testing MOMA-313, a drug that blocks a protein called DNA polymerase theta (Pol?) for prostate cancer with a genetic feature called homologous repair deficiency, most commonly with mutation in the gene BRCA2. The drug is being tested by itself or combined with another drug called olaparib, which blocks a different protein (PARP). There are two groups of patients: one group will get MOMA-313 alone, and the other group will get both MOMA-313 and olaparib. In the first group, doctors will test different doses to find the best amount that is effective and with the least amount of side effects to give patients. If patients do well but don't have a strong response to MOMA-313 alone, they may be switched to get both drugs together. The study will also look at how food ate by a patient affects MOMA-313 and how it interacts with olaparib.


Clinical Study Identifier: s24-00905
ClinicalTrials.gov Identifier: NCT06545942
Principal Investigator: David R. Wise.
Other Investigators: Scot Niglio, Minas Platon Economides, Hank Ng, Victor Ricardo Adorno Febles.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.